Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: A multicentre international study

Gut

Volumn 65, Issue 2, 2016, Pages 321-329

  Trivedi, Palak J ^a,b   Lammers, Willem J ^c   Van Buuren, Henk R ^c   Parés, Albert ^d   Floreani, Annarosa ^e   Janssen, Harry L A ^c,f   Invernizzi, Pietro ^g   Battezzati, Pier Maria ^h   Ponsioen, Cyriel Y ⁱ   Corpechot, Christophe ^j   Poupon, Raoul ^j   Mayo, Marlyn J ^k   Burroughs, Andrew K ^l   Nevens, Frederik ^m   Mason, Andrew L ⁿ   Kowdley, Kris V ^o,p   Lleo, Ana ^g   Caballeria, Llorenç ^d   Lindor, Keith D ^q,r   Hansen, Bettina E ^c   Hirschfield, Gideon M ^a,b   more..

^a University of Birmingham   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF PADOVA   (Italy)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j HÔPITAL SAINT ANTOINE   (France)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l ROYAL FREE HOSPITAL   (United Kingdom)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o VIRGINIA MASON MEDICAL CENTER   (United States)

^p SWEDISH MEDICAL CENTER   (United States)

^q MAYO CLINIC   (United States)

^r ARIZONA STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; URSODEOXYCHOLIC ACID;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; THROMBOCYTOPENIA; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; EUROPE; KAPLAN MEIER METHOD; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; METABOLISM; MULTICENTER STUDY; NORTH AMERICA; PROPORTIONAL HAZARDS MODEL; RISK; RISK FACTOR; STATISTICAL MODEL;

ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; NORTH AMERICA; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS; SEX FACTORS; THROMBOCYTOPENIA; URSODEOXYCHOLIC ACID;

EID: 84958871648     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308351     Document Type: Article

References (40)

1. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
2. Huet P-M, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: Effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008; 135: 1552-60.
3. Trivedi PJ, Bruns T, Cheung A, et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 2014; 60: 1249-58.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.
5. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
6. Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-20.
7. Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.
8. Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55: 1361-7.
9. Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105: 2186-94.
10. Jackson H, Solaymani-Dodaran M, Card TR, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study. Hepatology 2007; 46: 1131-7.
11. Kuiper EMM, Hansen BE, Adang RPR, et al. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2010; 22: 1495-502.
12. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
13. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
14. Suzuki A, Lymp J, Donlinger J, et al. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 259-64.
15. Imam MH, Silveira MG, Sinakos E, et al. Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012; 10: 182-5.
16. Cavazza A, Caballería L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers. Hepatology 2009; 50: 1162-8.
17. Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008; 48: 1149-56.
18. Hosonuma K, Sato K, Yanagisawa M, et al. Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis. Gastroenterol Res Pract 2013; 2013: 168012.
19. Findor J, He X-S, Sord J, et al. Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev 2002; 1: 220-5.
20. Caballería L, Parés A, Castells A, et al. Hepatocellular carcinoma in primary biliary cirrhosis: Similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001; 96: 1160-3.
21. Jones DE, Metcalf JV, Collier JD, et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26: 1138-42.
22. Shibuya A, Tanaka K, Miyakawa H, et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 2002; 35: 1172-8.
23. Floreani A, Farinati F. Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. Hepatology 2013; 58: 1520-1.
24. Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: National data from Japan. Hepatology 2013; 57: 1942-9.
25. Lammers WJ, Van Buuren H, Pares A et al. Defining optimal laboratory response criteria in UDCA treated primary biliary cirrhosis. Results of an international multicenter long-term follow-up study. Hepatology 2013; 58: 36A-91A.
26. Ter Borg PCJ, Schalm SW, Hansen BE, et al. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 2044-50.
27. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013; 144: 560-9.e7.
28. Silveira MG, Brunt EM, Heathcote J, et al. American Association for the Study of Liver Diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010; 52: 349-59.
29. Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-8.
30. Cummings P. Missing data and multiple imputation. JAMA Pediatr 2013; 167: 656-61.
31. Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis. Hepatology 2012; 56: 1409-17.
32. Boonstra K, Bokelaar R, Stadhouders PH, et al. Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: Follow-up for up to 36 years. Hepatol Int 2014; 8: 266-74.
33. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.
34. Melia WM, Johnson PJ, Neuberger J, et al. Hepatocellular carcinoma in primary biliary cirrhosis: Detection by alpha-fetoprotein estimation. Gastroenterology 1984; 87: 660-3.
35. Patanwala I, McMeekin P, Walters R, et al. A validated clinical tool for the prediction of varices in PBC: The Newcastle Varices in PBC Score. J Hepatol 2013; 59: 327-35.
36. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.
37. Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198-208.
38. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-27.
39. Nishikawa H, Kimura T, Kita R, et al. Treatment for hepatocellular carcinoma in elderly patients: A literature review. J Cancer 2013; 4: 635-43.
40. Trivedi PJ, Cullen S. Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Dig Dis Sci 2011; 56: 276-8.